Special Issue

Pharmacokinetics and Pharmacometrics Driving Innovation

Message from the Guest Editors

Pharmacokinetics (PK) and pharmacometrics (PMx) have long been central in elucidating drug disposition and guiding pharmacotherapy. Their role has expanded from determining concentration-time profiles to shaping drug development, regulatory science, and clinical practice. By quantifying drug disposition and exposure-response relationships, PK and PMx provide critical insights that can be utilized to improve the safety, efficacy, and individualization of therapy. For this Special Issue of Pharmaceuticals, "Pharmacokinetics and Pharmacometrics Driving Innovation", we welcome contributions demonstrating how PK and PMx generate new therapeutic opportunities or optimize existing ones. Submission topics may include, but are not limited to, the following:

- Regulatory applications with PBPK/PBBM, IVIVC/IVIVR, exposure-response analyses, and case studies on DDIs or food effects:
- Early in silico, animal, and translational studies, including microdosing, microtracers, and sparse or opportunistic sampling;
- Dose optimization and individualization through clinical PK, TDM, Bayesian forecasting, pharmacogenomics, and real-world data...

Guest Editors

Dr. Michel L Campos

Institutos de Ciências da Saúde (ICS), Federal University of Mato Grosso, Sinop, Mato Grosso, Brazil

Dr. Marcelo Gomes Davanço

Medical and Clinical Affairs Department, Knight Therapeutics, Sao Paulo 04085-001, Brazil

Dr. Mariana Millan Fachi

Hospital Alemão Oswaldo Cruz, Sao Paulo, Brazil

Deadline for manuscript submissions

12 March 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/257229

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

